Glycerophosphorylcholine

Template:Short description Template:Cs1 config Template:Short description Template:Template other{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals= | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=82016[O-]P(=O)(OC[C@H](O)CO)OCC[N+](C)(C)C1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1SUHOQUVVVLNYQR-MRVPVSSYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= N07 | _legal_data=OTC

| _other_data=[(2R)-2,3-Dihydroxypropyl] 2-trimethylazaniumylethyl phosphate

| _image_0_or_2 = L-alpha-GPC Structural Formula V.1.svgAGPCTHREED.png | _image_LR =

| _datapage = Glycerophosphorylcholine (data page) | _vaccine_target=_type_not_vaccine | _legal_all=OTC | _ATC_prefix_supplemental=N07 | _has_EMA_link = | CAS_number=28319-77-9 | PubChem=657272 | ChemSpiderID=571409 | ChEBI=55397 | ChEMBL=1567463 | DrugBank= | KEGG= | _hasInChI_or_Key=yes | UNII=60M22SGW66 | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs= | _countIndexlabels= | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=458279808}}

L-α-Glycerophosphorylcholine (alpha-GPC, choline alfoscerate, sn-glycero-3-phosphocholine) is a natural choline compound found in the brain. It is also a parasympathomimetic acetylcholine precursor which has been investigated for its potential for the treatment of Alzheimer's disease and other dementias.

Alpha-GPC rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of acetylcholine. It is a non-prescription drug in most countries. The FDA determined that intake of no more than 196.2 mg/person/day is considered generally recognized as safe (GRAS).

Production

Industrially, alpha-GPC is produced by the chemical or enzymatic deacylation of phosphatidylcholine enriched soya phospholipids followed by chromatographic purification. Alpha-GPC may also be derived in small amounts from highly purified soy lecithin as well as from purified sunflower lecithin.

Safety

A retrospective cohort study involving 12 million participants in South Korea found that α-GPC users had a higher risk of stroke ( + 46 % ). The authors suggested that one possible explanation is that dysbiosis may lead to α-GPC being metabolized into trimethylamine (TMA) in the gastrointestinal tract, and then to trimethylamine N-oxide (TMAO) in the liver, which has implications for cardiovascular health. However, they also noted that the study could be influenced by confounding variables, as α-GPC is often prescribed to individuals with preexisting health risks.

A later systematic review and meta-analysis criticized the statistical analysis of the South Korean cohort study, describing it as questionable and imprecise. The review concluded that α-GPC has a favorable safety and tolerability profile and is effective in improving cognitive function and daily living in patients with dementia disorders of neurological origin, adult-onset vascular dementia, and Alzheimer’s disease.

External links

• Alpha-GPC on PsychonautWiki